Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Mattia GalliFrancesco FranchiFabiana RolliniLatonya BeenPatrick Abou JaoudeAndrea RivasXuan ZhouSida JiaNaji MaalikiChang Hoon LeeAndres M PinedaSiva SuryadevaraDaniel SofferMartin M ZenniTobias GeislerLisa K JenningsTheodore A BassDominick J AngiolilloPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
ClinicalTrials.gov identifier: NCT03718429.